#THTX

Theratechnologies Reports Financial Results for the Second Quarter 2025 Theratechnologies (NASDAQ: THTX) reported Q2 2025 financial results with total revenue of $17.7 million, marking a 19.5% year-over-year decrease. For the first six months of 2025, revenue reached $36.8 million, down 3.9% from 2024. The company achieved positive Adjusted EBITDA for the fifth consecutive quarter, reaching $906,000 in Q2 2025.EGRIFTA SV® sales declined 31.3% to $11.1 million in Q2, primarily due to supply disruption and higher government chargebacks. Trogarzo® net sales increased 13.4% to $6.6 million. The company reported a net loss of $4.5 million for Q2 2025, compared to a net profit of $987,000 in Q2 2024.Subsequent to the quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak, leading to the withdrawal of its Fiscal 2025 guidance.

8 months ago

#THTX Theratechnologies Reports Financial Results for the Second Quarter 2025

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

8 months ago

Theratechnologies shareholders should take the deal, Research Capital says Research Capital analyst Andre Uddin is recommending Theratechnologies shareholders tender their shares to the proposed US$4.20 per share acquisition offer

Theratechnologies shareholders should take the deal, Research Capital says Research Capital analyst Andre Uddin is recommending Theratechnologies (Theratechnologies Stock Quote, Chart, News, Analys...

#All #posts #Analysts #Life #Sciences #thtx

Origin | Interest | Match

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading Thu Jul 3rd - #GITS #CMND #TRIP #THTX #OST #MINM #XPOF #OLO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Theratechnologies Earnings Coming Next Week: Final Results Before Acquisition Closes Last financial report before acquisition completion. No earnings call scheduled due to pending buyout. See how Theratechnologies performed in Q2 2025. Get details.

8 months ago

#THTX Theratechnologies to Announce Second Quarter 2025 Financial Results

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak Theratechnologies (NASDAQ: THTX) has entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, in a deal valued at up to US$254 million. Shareholders will receive US$3.01 in cash per share plus one contingent value right (CVR) worth up to US$1.19 in additional payments tied to specific milestones.The transaction represents a substantial premium of 126% (cash only) and 216% (including CVR) to THTX's Nasdaq closing price on April 10, 2025. The deal includes milestone payments linked to EGRIFTA franchise performance and combined EGRIFTA-Trogarzo franchise profits over a 36-month period post-closing.The transaction, expected to close in Q4 2025, requires 66⅔% shareholder approval and court approval. Upon completion, Theratechnologies will become private and delist from both Nasdaq and TSX.

8 months ago

#THTX Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Theratechnologies Shareholders Show Strong Support: 84% Approval for Board Nominees at Annual Meeting Latest shareholder meeting results reveal strong board support, new incentive plan approval, and auditor appointment. See complete voting breakdown.

9 months ago

#THTX Theratechnologies Reports on its Annual Meeting of Shareholders

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Major Acquisition Alert: Theratechnologies Opens Sale Process Following Buyout Interest Theratechnologies initiates formal sale process after Future Pak proposal. Raymond James and Norton Rose Fulbright join advisory team. See potential implications.

11 months ago

#THTX Theratechnologies Provides Update on Sale Process

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Mon Apr 14th - #THTX #VSG #VLN #NVRO #KRP #IH #CNF #OCX #LWAY #KOPN #HYPR #BTCS #ANTE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Anu Bansal

@stockholderrights.bsky.social

11 months ago

#THTX shareholder activism

Shareholders may be unhappy with #THTX management. Soleus Capital has filed 13Ds urging change.

To discuss this or other activism please message us: anu@stockholderdemocracy.com

0 0 0 0

Acquisition Battle Heats Up: Theratechnologies Reveals New Exclusive Buyer After $100M Offer Exclusive negotiations underway with new potential buyer following $100M offer from Future Pak. Company plans 'go shop' period to maximize shareholder value. Full details inside.

11 months ago

#THTX Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Massive 238% Premium: Future Pak Makes $255M Cash-Rich Bid for Theratechnologies Latest acquisition bid includes $205M cash upfront plus $50M in contingent payments. Deal offers premium up to 238% with no financing contingency. See full terms inside.

11 months ago

#THTX Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

www.stocktitan.net/news/THTX/future-pak-sub...

0 0 0 0

FDA Green Light: EGRIFTA SV Gains Full Distribution Rights as Sole HIV Lipodystrophy Treatment FDA removes distribution restrictions for EGRIFTA SV, the only approved treatment for HIV-related lipodystrophy. New formulation enhances patient experience. Full analysis inside.

11 months ago

#THTX Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Theratechnologies Q1 Earnings: CEO and Executive Team to Reveal Latest Financial Performance Full executive team to present Q1 2025 results on April 9. Join CEO, CFO, CMO, and Commercial Officer for comprehensive financial analysis and strategic insights.

11 months ago

#THTX Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment Getting your Trinity Audio player ready... Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continu...

11 months ago

JUST IN: ( NASDAQ: #THTX ) Theratechnologies Scores FDA Win with EGRIFTA WR: A Leaner, Smarter Fat-Fighter for HIV Patients

0 0 0 0

Giants67

@giants1967.bsky.social

11 months ago

#HIT Pushing Healthcare Boundaries
#OSRH #THTX #CSDX
thestreetreports.com/driving-the-...

0 0 0 0

Major FDA Win: New Weekly HIV Drug Cuts Treatment Burden by 85% Revolutionary weekly formulation reduces injection frequency from daily to weekly. New EGRIFTA WR shows improved convenience for HIV patients. Full analysis inside.

11 months ago

#THTX Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Breakthrough: Theratechnologies HIV Treatment Matches Standard Care in Challenging Cases New PROMISE-US data reveals Theratechnologies' ibalizumab achieves comparable viral suppression in severe HIV cases, with excellent safety profile and no treatment discontinuations.

1 year ago

#THTX Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 Theratechnologies (NASDAQ: THTX) reported strong financial results for Q4 and FY2024, achieving record positive Adjusted EBITDA of $20 million (net loss of $8.3 million) and annual revenue of $85.9 million.Key highlights include:Record quarterly revenue of $25 million in Q4 2024EGRIFTA SV® sales reached $60.1 million, growing 12% year-over-yearSecured $75 million in new credit facilities with TD Bank and Investissement QuébecIn-licensed two new Ionis assets (olezarsen and donidalorsen) in CanadaResumed distribution of EGRIFTA SV® following temporary supply disruptionFDA assigned March 25, 2025 PDUFA date for F8 formulation

1 year ago

#THTX Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Q4 Earnings Preview: Theratechnologies CEO to Unveil Strategic Vision Alongside 2024 Financial Results Join Theratechnologies' leadership team on February 26 for Q4 and FY2024 results, featuring CEO insights and strategic updates in biotech advancement.

1 year ago

#THTX Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

Theratechnologies Warns of EGRIFTA SV Shortage, Awaits Critical FDA Response for HIV Medicine Key HIV treatment EGRIFTA SV faces supply disruption by mid-January 2025. Theratechnologies seeks FDA approval for new batches as pharmacies report stockouts of this exclusive medication.

1 year ago

#THTX Theratechnologies Provides Update on EGRIFTA SV® Supply

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

1 year ago

News; ( NASDAQ: #THTX ) Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV Manufacturing Environment

#StockMarket #News

0 0 0 0

Theratechnologies Seeks FDA Approval for EGRIFTA SV® Manufacturing Changes Amid Supply Concerns Theratechnologies awaits FDA review of manufacturing changes for EGRIFTA SV®, with current inventory projected to last until mid-January 2025, raising supply continuity questions.

1 year ago

#THTX Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0

1 year ago

JUST IN: ( NASDAQ: #THTX ) Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

#StockMarket #News

0 0 0 0

1 year ago

JUST IN: ( NASDAQ: #THTX ) Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

#StockMarket #News

0 0 0 0

Theratechnologies Secures Exclusive Rights to Two Breakthrough Rare Disease Drugs in $22.75M Deal | THTX Stock News Theratechnologies partners with Ionis Pharmaceuticals, gaining Canadian rights to olezarsen and donidalorsen for rare diseases, marking strategic expansion beyond HIV treatments.

1 year ago

#THTX Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

#news #stocks #investing

www.stocktitan.net/news/THTX/theratechnolog...

0 0 0 0